Label: DERMASORB TA COMPLETE KIT- triamcinolone acetonide cream with emollient cream

  • NDC Code(s): 0316-0202-01, 0316-1015-01
  • Packager: Crown Laboratories
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated November 15, 2013

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Chemically triamcinolone acetonide is pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-(11β, 16α) with the empirical formula C24H31O6 and molecular weight 434.50. Its structural formula is:

    TA Structure

    Each gram of Dermasorb™TA contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

    Close
  • CLINICAL PHARMACOLOGY

    Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.

    The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

    Pharmacokinetics

    The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

    Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See DOSAGE AND ADMINISTRATION).

    Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

    Close
  • INDICATIONS AND USAGE

    Dermasorb™TA is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

    Close
  • CONTRAINDICATIONS

    Dermasorb™TA is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

    Close
  • PRECAUTIONS

    General

    Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.

    Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

    Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

    Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS-Pediatric use).

    If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

    In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

    Information for the Patient

    Patients using topical corticosteroids should receive the following information and instructions:

    1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

    2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.

    3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

    4. Patients should report any signs of local adverse reactions especially under occlusive dressing.

    5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

    Close
  • Laboratory Tests

    The following tests may be helpful in evaluating the HPA axis suppression:

                   Urinary free cortisol test

                   ACTH stimulation test

    Close
  • Carcinogenesis, Mutagenesis, and Impairment of Fertility

    Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

    Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

    Close
  • Pregnancy Category C

    Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.

    Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

    Close
  • Nursing Mothers

    It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant.

    Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

    Close
  • Pediatric Use

    Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio.

    Hypothalamic-pituitary-adrenaI (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

    Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

    Close
  • ADVERSE REACTIONS

    The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

    Burning

    Itching

    Irritation

    Dryness

    Folliculitis

    Hypertrichosis

    Acneiform eruptions

    Hypopigmentation

    Perioral dermatitis

    Allergic contact dermatitis

    Maceration of the skin

    Secondary infection

    Skin Atrophy

    Striae

    Miliaria

    Close
  • OVERDOSAGE

    Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. See PRECAUTIONS

    Close
  • DOSAGE AND ADMINISTRATION

    Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.

    Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.

    If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

    Close
  • STORAGE AND PACKAGING

    Store at room temperature 15oC- 30oC (56oF- 86oF) in original container.

    Protect from freezing.

    Close
  • HOW SUPPLIED

    DERMASORB™TA (Triamcinolone Acetonide USP, 0.1%) Cream is supplied in:

    85.2 g tube NDC 0316-0202-01

    Rx ONLY

    PRINTED IN USA

    P6175.01

    Manufactured and Distributed by Crown Laboratories, Inc., Johnson City, TN 37604

    Close
  • Dermasorb TA Complete Kit

    p617601

    Dermasorb TA Trade Carton

    Close
  • INGREDIENTS AND APPEARANCE
    DERMASORB TA COMPLETE KIT 
    triamcinolone acetonide cream with emollient cream kit
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0316-1015
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0316-1015-01 1 in 1 KIT
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 2 TUBE 170.4 g
    Part 2 1 BOTTLE, PLASTIC 170 g
    Part 1 of 2
    DERMASORB TA 
    triamcinolone acetonide cream cream
    Product Information
    Item Code (Source) NDC:0316-0202
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII:F446C597KA) TRIAMCINOLONE ACETONIDE 1 mg  in 1 g
    Inactive Ingredients
    Ingredient Name Strength
    WATER (UNII: 059QF0KO0R)  
    POLAWAX POLYSORBATE (UNII: Q504PL8E0V)  
    MINERAL OIL (UNII: T5L8T28FGP)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    SORBITOL (UNII: 506T60A25R)  
    CETYL PALMITATE (UNII: 5ZA2S6B08X)  
    SORBIC ACID (UNII: X045WJ989B)  
    POTASSIUM SORBATE (UNII: 1VPU26JZZ4)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 2 in 1 KIT
    1 NDC:0316-0202-01 85.2 g in 1 TUBE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA088042 11/14/2013
    Part 2 of 2
    DERMASORB BARRIER REPAIR EMOLLIENT 
    lotions, oils, powders, and creams
    Product Information
    Other Ingredients
    Ingredient Kind Ingredient Name Quantity
    INGR WATER (UNII: 059QF0KO0R)  
    INGR PETROLATUM (UNII: 4T6H12BN9U)  
    INGR GLYCERIN (UNII: PDC6A3C0OX)  
    INGR MINERAL OIL (UNII: T5L8T28FGP)  
    INGR CETYL ALCOHOL (UNII: 936JST6JCN)  
    INGR STEARYL ALCOHOL (UNII: 2KR89I4H1Y)  
    INGR POLYOXYL 20 CETOSTEARYL ETHER (UNII: YRC528SWUY)  
    INGR ISONONYL ISONONANOATE (UNII: S4V5BS6GCX)  
    INGR ETHYLHEXYL ISONONANOATE (UNII: I6KB4GE3K4)  
    INGR CERAMIDE 3 (UNII: 4370DF050B)  
    INGR CAPRYLYL GLYCOL (UNII: 00YIU5438U)  
    INGR CHLORPHENESIN (UNII: I670DAL4SZ)  
    INGR PHENOXYETHANOL (UNII: HIE492ZZ3T)  
    INGR POLIHEXANIDE (UNII: 322U039GMF)  
    INGR CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
    INGR COW MILK FAT (UNII: 463JZS0XJ3)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 1 in 1 KIT
    1 170 g in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    cosmetic 11/14/2013
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA088042 11/14/2013
    Labeler - Crown Laboratories (079035945)
    Registrant - Crown Laboratories (079035945)
    Establishment
    Name Address ID/FEI Business Operations
    Crown Laboratories 079035945 manufacture(0316-1015)
    Close